List view / Grid view
21 May 2018 | By European Pharmaceutical Review
Machine learning has detected one of the commonest causes of dementia and stroke, in the most widely used form of brain scan (CT), more accurately than current methods.
18 April 2018 | By European Pharmaceutical Review
One class of drug used to treat type 2 diabetes may not reduce the risk of death when compared with placebo, suggests new findings...
6 April 2018 | By Dr Zara Kassam (European Pharmaceutical Review)
A new clinical study will test for the first time if MRI scans can be used for population screening to detect prostate cancer more accurately...
3 April 2018 | By Dr Zara Kassam (European Pharmaceutical Review)
The EC has approved Alofisel for the treatment of complex perianal fistulae in adult patients with nonactive/mildly active luminal Crohn’s disease...
15 March 2018 | By Dr Zara Kassam (European Pharmaceutical Review)
A new class of experimental drugs reduces hot flushes in menopausal women by almost three-quarters in just three days...
8 February 2018 | By Dr Zara Kassam (European Pharmaceutical Review)
Health Data Research UK is awarding £30 million funding to six sites across the UK to address challenging healthcare issues through the use of data science...
10 January 2018 | By Dr Zara Kassam (European Pharmaceutical Review)
A new 3D printing technique allows researchers to replicate biological structures, which could be used for tissue regeneration and replica organs...
24 November 2017 | By Dr Zara Kassam (European Pharmaceutical Review)
An immunotherapy drug can be used to cure a rare type of cancer arising from pregnancy when existing treatments have failed...
23 November 2017 | By Dr Zara Kassam (European Pharmaceutical Review)
Glatiramer acetate, a drug used to treat multiple sclerosis, has been found to have an effect on drug-resistant bacteria...
7 June 2017 | By Niamh Marriott, Junior Editor
Data has shown similarity in efficacy and safety between CT-P6 (biosimilar trastuzumab candidate) and reference trastuzumab treatment in patients...
6 April 2017 | By Niamh Marriott, Junior Editor
In a trial carried out at Imperial College, researchers showed that women who suffered seven or more hot flushes a day could reduce the number by 73%...
8 November 2016 | By Niamh Louise Marriott, Digital Content Producer
Mucosis has begun a first-in-human study of its intranasal Respiratory Syncytial Virus (RSV) vaccine candidate, SynGEM, at Imperial College London...
15 July 2015 | By Victoria White
Scientists have discovered a new subtype of emm89 streptococcus that has contributed to a rise in disease cases in the UK over the last 17 years...
3 July 2015 | By Victoria White
A therapy that replaces the faulty gene responsible for cystic fibrosis in patients' lungs has produced encouraging results in a major UK trial...
18 April 2013 | By Pedro R. Cutillas, MRC Clinical Sciences Centre, Imperial College London
Not all cancer patients, even those with the same tumour type, respond to therapy equally well. An understanding of this heterogeneity at the molecular level is crucial for further advances in the development of cancer therapies. Discerning the mechanisms of cancer heterogeneity will lead to a better selection of the…
Send this to a friend
Follow: